search
Back to results

Success Rate, Continence, and Quality of Life With a Bioprosthetic Plug for Treating Complex Anal Fistula

Primary Purpose

Complex Anal Fistula

Status
Completed
Phase
Phase 2
Locations
Switzerland
Study Type
Interventional
Intervention
Anal fistula plug
Sponsored by
University Hospital, Basel, Switzerland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Complex Anal Fistula focused on measuring anal fistula, anal continence, health-related quality of life

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Complex anal fistula as defined by

  • high transsphincteric fistula
  • extrasphincteric fistula
  • suprasphincteric fistula
  • recurrent fistula
  • multiple fistula openings, including horseshoe fistula
  • imperfect continence- jeopardized anal continence (anterior transsphincteric fistula, prior anal surgery)

Exclusion Criteria:

  • Uncomplicated fistula curable by simple fistulotomy
  • History of inflammatory bowel disease
  • Chronic immunosuppressive treatment (ie, systemic steroids for >3 days)
  • Clinical heart failure as defined by a CCS angina severity class ≥ III
  • Untreated cancer or cancer diagnosed/treated (all modalities) within 6 months
  • Estimated life expectancy inferior to 6 months
  • Incompetent subject
  • Pregnancy

Sites / Locations

  • University of Basel & Kantonsspital St.Gallen

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Anal fistula plug

Arm Description

Outcomes

Primary Outcome Measures

Fistula healing
Clinical healing of a complex anal fistula as assessed in the clinic at 6 weeks and 6 months after anal fistula plug surgery. Further assessment prn.
Anal continence
Evaluation of anal continence by means of a validated questionnaire, namely the Fecal Incontinence Severity Index, at 6 weeks and 6 months after anal fistula plug surgery.
Quality of life
Evaluation of health-related quality of life by means of a validated questionnaire, namely the Short-Form 36 version 2, at 6 weeks and 6 months after anal fistula plug surgery.

Secondary Outcome Measures

Full Information

First Posted
June 2, 2012
Last Updated
May 16, 2013
Sponsor
University Hospital, Basel, Switzerland
Collaborators
Unity Health Toronto, Women's College Hospital, St. Claraspital AG, Mount Sinai Hospital, Canada
search

1. Study Identification

Unique Protocol Identification Number
NCT01612195
Brief Title
Success Rate, Continence, and Quality of Life With a Bioprosthetic Plug for Treating Complex Anal Fistula
Official Title
Success Rate, Continence, and Quality of Life With a Bioprosthetic Plug for Treating Complex Anal Fistula
Study Type
Interventional

2. Study Status

Record Verification Date
May 2013
Overall Recruitment Status
Completed
Study Start Date
January 2007 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
January 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital, Basel, Switzerland
Collaborators
Unity Health Toronto, Women's College Hospital, St. Claraspital AG, Mount Sinai Hospital, Canada

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Anal abscess-fistula disease is of common occurrence and has a significant impact on the quality of life of affected individuals. The course of abscess-fistula disease as well as its treatment modalities may affect anal continence. The present cohort study investigates the results of anal fistula plug surgery. In particular, this study focus on the impact of anal fistula plug surgery on fistula healing, quality of life, and anal continence. Fifty patients will be included and followed up at 6 weeks and 6 months after surgery in the clinic of participating surgeons.
Detailed Description
Anal abscess-fistula disease is of common occurrence and has a significant impact on the quality of life of affected individuals. The clinical course of abscess-fistula disease as well as its treatment modalities may affect anal continence. Anal fistula plug surgery is an Health Canada and FDA approved surgical treatment that has demonstrated promising results in terms of fistula healing and minimal patients' burden. The present cohort study prospectively investigates the results of anal fistula plug surgery performed in teaching hospitals affiliated to the University of Toronto. In particular, this study focus on the impact of anal fistula plug surgery on health-related quality of life, and its 2 major determinants anal continence and fistula healing. Fifty patients will be included and followed up at 6 weeks and 6 months after surgery in the clinic of participating surgeons. Quality of life and anal continence will be measured with the validated Short Form-36 Health Survey (SF-36 v2) and Fecal Incontinence Score Index (FISI) questionnaires, respectively. It is expected that the present study will provide objective information on the results and generalizability of anal fistula surgery, as well as on its impact on health-related quality of life and anal continence.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Complex Anal Fistula
Keywords
anal fistula, anal continence, health-related quality of life

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
46 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Anal fistula plug
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
Anal fistula plug
Other Intervention Name(s)
Anal fistula plug Surgisis®
Intervention Description
All patients have a draining seton for at least 6 weeks prior placement of the anal fistula plug. All patients are administered a general anesthetic and are operated in the lithotomy position. The seton is removed, but no curettage or irrigation of the fistula tract is performed. The plug is inserted through the internal opening, and pulled through the external opening until it fit snugly and its base is sutured to the internal sphincter with 2 interrupted 2-0 polyglactin 910 sutures. The tip of the plug is cut at skin level and not sutured. The external opening is left open to allow for drainage. The patient is instructed to restrict physical and sexual activity for 2 weeks postoperatively. Patients are seen in the post-operative clinic at 10 days, 6 weeks and 6 months as per protocol.
Primary Outcome Measure Information:
Title
Fistula healing
Description
Clinical healing of a complex anal fistula as assessed in the clinic at 6 weeks and 6 months after anal fistula plug surgery. Further assessment prn.
Time Frame
6 months
Title
Anal continence
Description
Evaluation of anal continence by means of a validated questionnaire, namely the Fecal Incontinence Severity Index, at 6 weeks and 6 months after anal fistula plug surgery.
Time Frame
6 months
Title
Quality of life
Description
Evaluation of health-related quality of life by means of a validated questionnaire, namely the Short-Form 36 version 2, at 6 weeks and 6 months after anal fistula plug surgery.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Complex anal fistula as defined by high transsphincteric fistula extrasphincteric fistula suprasphincteric fistula recurrent fistula multiple fistula openings, including horseshoe fistula imperfect continence- jeopardized anal continence (anterior transsphincteric fistula, prior anal surgery) Exclusion Criteria: Uncomplicated fistula curable by simple fistulotomy History of inflammatory bowel disease Chronic immunosuppressive treatment (ie, systemic steroids for >3 days) Clinical heart failure as defined by a CCS angina severity class ≥ III Untreated cancer or cancer diagnosed/treated (all modalities) within 6 months Estimated life expectancy inferior to 6 months Incompetent subject Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michel Adamina, MD, PD, MSc
Organizational Affiliation
University of Basel
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Basel & Kantonsspital St.Gallen
City
Basel & St.Gallen
ZIP/Postal Code
4031 & 9007
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

Success Rate, Continence, and Quality of Life With a Bioprosthetic Plug for Treating Complex Anal Fistula

We'll reach out to this number within 24 hrs